Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012

Annals of Epidemiology

Volumn 24, Issue 5, 2014, Pages 369-375

  Magee, Matthew J ^a   Foote, Mary ^b   Maggio, David M ^c   Howards, Penelope P ^a   Narayan, K M Venkat ^a   Blumberg, Henry M ^a,b   Ray, Susan M ^b   Kempker, Russell R ^b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATSDR (MS: E 31)   (United States)

Author keywords

Diabetes mellitus; Georgia; HIV; Mortality; Tuberculosis

Indexed keywords

GLUCOSE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIRECTLY OBSERVED THERAPY; DISEASE ASSOCIATION; DRUG SENSITIVITY; DRUG USE; END STAGE RENAL DISEASE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GLUCOSE BLOOD LEVEL; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OCCUPATION; PATIENT INFORMATION; PRIORITY JOURNAL; PRISON; RETROSPECTIVE STUDY; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNEMPLOYMENT; UNITED STATES; CAUSE OF DEATH; COINFECTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; FOLLOW UP; GEORGIA; HIV INFECTIONS; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SELF REPORT; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CAUSE OF DEATH; COINFECTION; COMORBIDITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GEORGIA; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SELF REPORT; TUBERCULOSIS; YOUNG ADULT;

EID: 84899911030     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2014.01.012     Document Type: Article

References (36)

1. Trends in tuberculosis-United States, 2012. MMWR Morb Mortal Wkly Rep 2013, 62(11):201-205.
2. Reported Tuberculosis in the United States, 2011 2012, CDC, Department of Health and Human Services, CDC, Atlanta, GA: USA.
3. Garcia-Garcia Mde L., Ponce-De-Leon A., Garcia-Sancho M.C., Ferreyra-Reyes L., Palacios-Martinez M., Fuentes J., et al. Tuberculosis-related deaths within a well-functioning DOTS control program. Emerg Infect Dis 2002, 8(11):1327-1333.
4. Kliiman K., Altraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14(4):454-463.
5. Espinal M.A., Kim S.J., Suarez P.G., Kam K.M., Khomenko A.G., Migliori G.B., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000, 283(19):2537-2545.
6. Marks S.M., Magee E., Robison V. Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus. Int J Tuberc Lung Dis 2011, 15(4):465-470.
7. Au-Yeung C., Kanters S., Ding E., Glaziou P., Anema A., Cooper C.L., et al. Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol 2011, 3:21-29.
8. Porkert M.T., Sotir M., Parrott-Moore P., Blumberg H.M. Tuberculosis meningitis at a large inner-city medical center. Am J Med Sci 1997, 313(6):325-331.
9. Kourbatova E.V., Leonard M.K., Romero J., Kraft C., del Rio C., Blumberg H.M. Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US. Eur J Epidemiol 2006, 21(9):715-721.
10. Sterling T.R., Zhao Z., Khan A., Chaisson R.E., Schluger N., Mangura B., et al. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. Int J Tuberc Lung Dis 2006, 10(5):542-549.
11. Kourbatova E.V., Borodulin B.E., Borodulina E.A., del Rio C., Blumberg H.M., Leonard M.K. Risk factors for mortality among adult patients with newly diagnosed tuberculosis in Samara, Russia. Int J Tuberc Lung Dis 2006, 10(11):1224-1230.
12. Walpola H.C., Siskind V., Patel A.M., Konstantinos A., Derhy P. Tuberculosis-related deaths in Queensland, Australia, 1989-1998: characteristics and risk factors. Int J Tuberc Lung Dis 2003, 7(8):742-750.
13. Raviglione M., Marais B., Floyd K., Lonnroth K., Getahun H., Migliori G.B., et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012, 379(9829):1902-1913.
14. Cowie C.C., Rust K.F., Byrd-Holt D.D., Gregg E.W., Ford E.S., Geiss L.S., et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010, 33(3):562-568.
15. Jeon C.Y., Murray M.B. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008, 5(7):e152.
16. Dooley K.E., Chaisson R.E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009, 9(12):737-746.
17. Baker M.A., Harries A.D., Jeon C.Y., Hart J.E., Kapur A., Lonnroth K., et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011, 9(1):81.
18. Oursler K.K., Moore R.D., Bishai W.R., Harrington S.M., Pope D.S., Chaisson R.E. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis 2002, 34(6):752-759.
19. Dooley K.E., Tang T., Golub J.E., Dorman S.E., Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg 2009, 80(4):634-639.
20. Restrepo B.I., Fisher-Hoch S.P., Crespo J.G., Whitney E., Perez A., Smith B., et al. Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007, 135(3):483-491.
21. 2011 Georgia Tuberculosis Report 2012, GDPH, Georgia Department of Public Health, Atlanta.
22. Kleinbaum D., Klein M. Survival analysis: a self-learning text 2012, Springer, New York. 3rd ed.
23. Greenland S., Pearl J., Robins J.M. Causal diagrams for epidemiologic research. Epidemiology 1999, 10(1):37-48.
24. Diabetes Atlas, Update 2012 2012, IDF, International Diabetes Federation, Brussels.
25. Oluboyo P.O., Erasmus R.T. The significance of glucose intolerance in pulmonary tuberculosis. Tubercle 1990, 71(2):135-138.
26. Niemi M., Backman J.T., Neuvonen M., Neuvonen P.J., Kivisto K.T. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001, 69(6):400-406.
27. Kapur A., Harries A.D. The double burden of diabetes and tuberculosis-public health implications. Diabetes Res Clin Pract 2013, 101(1):10-19.
28. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 2008, 3(6):399-407.
29. Restrepo B.I., Fisher-Hoch S.P., Pino P.A., Salinas A., Rahbar M.H., Mora F., et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008, 47(5):634-641.
30. Stalenhoef J.E., Alisjahbana B., Nelwan E.J., van der Ven-Jongekrijg J., Ottenhoff T.H., van der Meer J.W., et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008, 27(2):97-103.
31. Banerjee D., Bhattacharyya R., Kaul D., Sharma P. Diabetes and tuberculosis: analysis of a paradox. Adv Clin Chem 2011, 53:139-153.
32. Kumar N.P., Sridhar R., Banurekha V.V., Jawahar M.S., Nutman T.B., Babu S. Expansion of pathogen-specific T-helper 1 and T-helper 17 cells in pulmonary tuberculosis with coincident type 2 diabetes mellitus. J Infect Dis 2013, 208(5):739-748.
33. Moutschen M.P., Scheen A.J., Lefebvre P.J. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992, 18(3):187-201.
34. Fielder J.F., Chaulk C.P., Dalvi M., Gachuhi R., Comstock G.W., Sterling T.R. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis 2002, 6(12):1114-1117.
35. Faurholt-Jepsen D., Range N., Praygod G., Jeremiah K., Faurholt-Jepsen M., Aabye M.G., et al. Diabetes is a strong predictor of mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients from Mwanza, Tanzania. Trop Med Int Health 2013, 18(7):822-829.
36. Rothman K., Greenland S., Lash T. Modern epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia. 3 ed.